LL-37 (16-32)[E1G; F2,12BIP; I5,9l; L13l], GF-17BIPHE2
General Information
DRACP ID DRACP03720
Peptide Name LL-37 (16-32)[E1G; F2,12BIP; I5,9l; L13l], GF-17BIPHE2
Sequence GXKRlVQRlKDXlRNLV
Sequence Length 17
UniProt ID P49913
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antibacterial; Antiviral
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral Mix
Physicochemical Information
Formula C61H103N25O12
Absent amino acids ACEFHIMPSTWY
Common amino acids R
Mass 188421
Pl 12.24
Basic residues 5
Acidic residues 1
Hydrophobic residues 3
Net charge 4
Boman Index -6282
Hydrophobicity -117.65
Aliphatic Index 57.06
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 2
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 34959645
Title Structure and Activity of a Selective Antibiofilm Peptide SK-24 Derived from the NMR Structure of Human Cathelicidin LL-37
Doi Not available
Year 2021
Literature 2
Pubmed ID 32252021
Title Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection
Doi Not available
Year 2020
Literature 3
Pubmed ID 30800727
Title Amino Acid Composition Determines Peptide Activity Spectrum and Hot-Spot-Based Design of Merecidin
Doi Not available
Year 2018
Literature 4
Pubmed ID 28450045
Title Arginine-lysine positional swap of the LL-37 peptides reveals evolutional advantages of the native sequence and leads to bacterial probes
Doi Not available
Year 2017
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
External Code
DBAASP ID 11854